Focuses on steps taken by the U.S. Food and Drug Administration and the National Institutes of Health to deal with the widespread concerns regarding gene therapy. Meeting held to review the safety findings preclinical testing and gene therapy clinical trials; Reasons for the complications in the assessment of the safety of gene-therapy procedures; Complications in the clinical use of adenovirus-based gene vectors.